- The major vendors in the Global Pneumococcal Vaccines Market are GlaxoSmithKline plc, Merck & Co. Inc. and Pfizer Inc.
London, 04 September 2014: TechNavio, an independent tech-focused global research firm, announced today the publication of its market research report on the Global Pneumococcal Vaccines Market 2014-2018. . One of the growing trends in this market is strategic alliances of vendors, resulting in consolidation. Such alliances increase the market penetration of the acquirer or to enhance the product portfolio of the parent company. An increase in the prevalence of pneumococcal diseases, coupled with a rise in awareness, is expected to drive the market during the forecast period of 2013-2018.
Pneumococcus causes pneumonia, sinusitis, blood infections, meningitis, and middle ear infections. Pneumococcal diseases predominantly affect young children and the elderly killing as many as 1.6 million people every year. These diseases can be prevented by vaccination which involves the introduction of dead or weakened antigens into the human body, which in turn produce lymphocytes to counter infection and any future invasions by that particular antigen.
“The growth of the Global Pneumococcal Vaccines market is expected to be propelled by the prevalence of pneumococcal diseases, especially in the APAC region and other developing nations,” says Faisal Ghaus, Vice President of TechNavio Research.
To define the market conditions in the next 3-4 years, TechNavio analysts have conducted in-depth analysis of the impact of market drivers, challenges and trends featuring data on product segmentations, vendor shares, growth rate by revenue and an evaluation of the different buying criteria in the order of importance.
https://www.technavio.com/%3Cp%3EIf%20you%20are%20interested%20in%20more%…
